Evidence map›Paper›PMID 39036087›Full record

ArticleBioengineering & translational medicine2024

Human induced pluripotent stem cells-derived liver organoids grown on a Biomimesys® hyaluronic acid-based hydroscaffold as a new model for studying human lipoprotein metabolism.

Meryl Roudaut, Amandine Caillaud, Zied Souguir, Lise Bray, Aurore Girardeau, Antoine Rimbert, Mikaël Croyal, Gilles Lambert, Murielle Patitucci, Gaspard Delpouve and 5 more

Abstract read
In one paragraph

Article in Bioengineering & translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Meryl RoudautNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.ORCID https://orcid.org/0000-0003-2373-7593
Amandine CaillaudNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.ORCID https://orcid.org/0000-0001-6409-2336
Zied SouguirHCS Pharma Lille France.
Lise BrayNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Aurore GirardeauNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Antoine RimbertNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Mikaël CroyalNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Gilles LambertInserm, UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI) Université de La Réunion Saint-Denis de La Réunion France.
Murielle PatitucciNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Gaspard DelpouveHCS Pharma Lille France.
Élodie VandenhauteHCS Pharma Lille France.
Cédric Le MayNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Nathalie MaubonHCS Pharma Lille France.
Bertrand CariouNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.
Karim Si-TayebNantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax Nantes France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The liver plays a key role in the metabolism of lipoproteins, controlling both production and catabolism. To accelerate the development of new lipid-lowering therapies in humans, it is essential to have a relevant in vitro study model available. The current hepatocyte-like cells (HLCs) models derived from hiPSC can be used to model many genetically driven diseases but require further improvement to better recapitulate the complexity of liver functions. Here, we aimed to improve the maturation of HLCs using a three-dimensional (3D) approach using Biomimesys®, a hyaluronic acid-based hydroscaffold in which hiPSCs may directly form aggregates and differentiate toward a functional liver organoid model. After a 28-day differentiation 3D protocol, we showed that many hepatic genes were upregulated in the 3D model (liver organoids) in comparison with the 2D model (HLCs). Liver organoids, grown on Biomimesys®, exhibited an autonomous cell organization, were composed of different cell types and displayed enhanced cytochromes P450 activities compared to HLCs. Regarding the functional capacities of these organoids, we showed that they were able to accumulate lipids (hepatic steatosis), internalize low-density lipoprotein and secrete apolipoprotein B. Interestingly, we showed for the first time that this model was also able to produce apolipoprotein (a), the apolipoprotein (a) specific of Lp(a). This innovative hiPSC-derived liver organoid model may serve as a relevant model for studying human lipopoprotein metabolism, including Lp(a).

Indexed as

cytochrome activitieshiPSC‐derived liver organoidshyaluronic‐acid based hydroscaffoldlipid metabolismliver steatosisLp(a)

Identifiers

PMID39036087
PMCPMC11256179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.